HYPAQUE SODIUM 20%
LOE ApproachingNDAURETERALSOLUTIONPriority Review
Approved
Nov 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYPAQUE SODIUM 20% is a contrast media solution administered via ureteral route for diagnostic imaging procedures. This iodinated contrast agent enhances visualization of the urinary tract during radiographic examination. The product has been a foundational diagnostic tool since 1954.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), requiring defensive commercial strategies and cost optimization initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYPAQUE SODIUM 20% positions professionals in GE HealthCare's diagnostic imaging division with emphasis on operational, engineering, and financial roles rather than commercial or medical innovation. This reflects a mature product requiring infrastructure optimization, cost management, and field support across regional markets (notably Japan).
Software Engineer
Worked on HYPAQUE SODIUM 20% at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.